OSI Pharmaceuticals Inc. (OSIP) said it now believes that the 2010 overall revenue percentage growth rate will be in the mid-teens and re-affirmed that adjusted earnings per share will grow at 10% or more. Analysts polled by Thomson Reuters expect the company to report earnings of $1.62 per share on revenues of $476.31 million for fiscal 2010. Analysts' estimates typically exclude special items.
The company also provided investors with an update on the re-purchase of a portion of its outstanding convertible debt bonds. As of December 22, 2009, the Company had purchased $39.5 million face value of the 2023 convertible bonds for $37.6 million and $40.0 million face value of the 2038 convertible bonds for $37.4 million. The aggregate amount of the Company's outstanding 2038 Notes, 2023 Notes and 2025 Notes at face value is now equal to $335.5 million. The company said that it may continue to selectively re-purchase convertible debt bonds and common stock throughout 2010.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.